Author
Listed:
- Tomas Kalincik
- Timothy Spelman
- Maria Trojano
- Pierre Duquette
- Guillermo Izquierdo
- Pierre Grammond
- Alessandra Lugaresi
- Raymond Hupperts
- Edgardo Cristiano
- Vincent Van Pesch
- Francois Grand’Maison
- Daniele La Spitaleri
- Maria Edite Rio
- Sholmo Flechter
- Celia Oreja-Guevara
- Giorgio Giuliani
- Aldo Savino
- Maria Pia Amato
- Thor Petersen
- Ricardo Fernandez-Bolanos
- Roberto Bergamaschi
- Gerardo Iuliano
- Cavit Boz
- Jeannette Lechner-Scott
- Norma Deri
- Orla Gray
- Freek Verheul
- Marcela Fiol
- Michael Barnett
- Erik van Munster
- Vetere Santiago
- Fraser Moore
- Mark Slee
- Maria Laura Saladino
- Raed Alroughani
- Cameron Shaw
- Krisztian Kasa
- Tatjana Petkovska-Boskova
- Leontien den Braber-Moerland
- Joab Chapman
- Eli Skromne
- Joseph Herbert
- Dieter Poehlau
- Merrilee Needham
- Elizabeth Alejandra Bacile Bacile
- Walter Oleschko Arruda
- Mark Paine
- Bhim Singhal
- Steve Vucic
- Jose Antonio Cabrera-Gomez
- Helmut Butzkueven
- on behalf of the MSBase Study Group ¶
Abstract
Objectives: To compare treatment persistence between two dosages of interferon β-1a in a large observational multiple sclerosis registry and assess disease outcomes of first line MS treatment at these dosages using propensity scoring to adjust for baseline imbalance in disease characteristics. Methods: Treatment discontinuations were evaluated in all patients within the MSBase registry who commenced interferon β-1a SC thrice weekly (n = 4678). Furthermore, we assessed 2-year clinical outcomes in 1220 patients treated with interferon β-1a in either dosage (22 µg or 44 µg) as their first disease modifying agent, matched on propensity score calculated from pre-treatment demographic and clinical variables. A subgroup analysis was performed on 456 matched patients who also had baseline MRI variables recorded. Results: Overall, 4054 treatment discontinuations were recorded in 3059 patients. The patients receiving the lower interferon dosage were more likely to discontinue treatment than those with the higher dosage (25% vs. 20% annual probability of discontinuation, respectively). This was seen in discontinuations with reasons recorded as “lack of efficacy” (3.3% vs. 1.7%), “scheduled stop” (2.2% vs. 1.3%) or without the reason recorded (16.7% vs. 13.3% annual discontinuation rate, 22 µg vs. 44 µg dosage, respectively). Propensity score was determined by treating centre and disability (score without MRI parameters) or centre, sex and number of contrast-enhancing lesions (score including MRI parameters). No differences in clinical outcomes at two years (relapse rate, time relapse-free and disability) were observed between the matched patients treated with either of the interferon dosages. Conclusions: Treatment discontinuations were more common in interferon β-1a 22 µg SC thrice weekly. However, 2-year clinical outcomes did not differ between patients receiving the different dosages, thus replicating in a registry dataset derived from “real-world” database the results of the pivotal randomised trial. Propensity score matching effectively minimised baseline covariate imbalance between two directly compared sub-populations from a large observational registry.
Suggested Citation
Tomas Kalincik & Timothy Spelman & Maria Trojano & Pierre Duquette & Guillermo Izquierdo & Pierre Grammond & Alessandra Lugaresi & Raymond Hupperts & Edgardo Cristiano & Vincent Van Pesch & Francois G, 2013.
"Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis,"
PLOS ONE, Public Library of Science, vol. 8(5), pages 1-9, May.
Handle:
RePEc:plo:pone00:0063480
DOI: 10.1371/journal.pone.0063480
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0063480. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.